The addition of a mTOR/PI3K inhibitor effectively controls cell growth in EGFR inhibitor-resistant HNSCC, suggesting that combination therapy may increase treatment efficacy (87, 88). The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.